Bridgebio Pharma

Bridgebio Pharma Inc. PAC (BRIDGEBIOPAC)

Corporate PAC FEC C00943522

Influence at a glance · Jan 2025 – Sep 2026Jan 25 – Sep 26 How we count

PAC giving to candidates$28K

Company lobbying, all issues $2.6M

Giving: FEC filings, net of refunds. Lobbying: the company’s own LD-2 reports, all issues, rounded to the nearest $10,000 each quarter. Two different filers, same 21 months.Lobbying: all issues, rounded to the nearest $10,000. Two filers, same 21 months. This PAC gives money raised from the company’s employees; the company itself can’t give to campaigns from its treasury.

Lobbying spend by quarter since 2015Spend by quarter Pro

Free account See Pro

What they lobby on

Method

Bridgebio Pharma reported federal lobbying in 8 of the last 8 quarters (Q4 2024 to Q3 2026), with its own in-house lobbyists and 3 outside firms. What follows is what the filings say it lobbied on, not which way.

Issue areas ranked by quarters filedQ4 24 → Q3 26

Pharmacy8 of 88/8
Health Issues2 of 82/8
Medicare/Medicaid2 of 82/8

Bills named in the filings 13 bills, this period

H.R. 1262 Mikaela Naylon Give Kids a Chance Act5 filings
S. 822 / H.R. 1532 Scientific EXPERT Act of 20255 filings
H.R. 1414 Cameron’s Law3 filings
H.R. 1 An act to provide for reconciliation pursuant to title II of H. Con. Res. 14. Broad bill3 filings
H.R. 10359 Priority for Pediatric Cures Act1 filing

8 more, 9 named in only one filing · Show all 13

H.R. 3433, 118th Give Kids a Chance Act of 20241 filing
H.R. 4317 PBM Reform Act of 20251 filing
H.R. 9979, 118th Scientific EXPERT Act of 20241 filing
S. 4583 / H.R. 7384, 118th Creating Hope Reauthorization Act of 20241 filing
S. 932 Give Kids a Chance Act of 20251 filing
H.R. 10545, 118th American Relief Act, 2025 Broad bill1 filing
H.R. 1968 Full-Year Continuing Appropriations and Extensions Act, 2025 Broad bill1 filing
H.R. 7148 Consolidated Appropriations Act, 2026 Broad bill1 filing

From the filings

“Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act Priority for Pediatric Cures Act (H.R.10359)”

Q3 2026 filing · Pharmacy

“Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act”

Q2 2026 filing · Pharmacy

Contacted as listed on the filings

U.S. House
U.S. Senate
Food & Drug AdministrationFDA
Centers For Medicare and Medicaid ServicesCMS
Health & Human ServicesHHS

The House and Senate appear in every quarter; agencies in 6 of 8.

Every filing since 2015, with the lobbyists named and the quarters each bill appearsEvery filing since 2015 Pro

Free account See Pro

Source: Lobbying Disclosure Act filings (LD-2) by Bridgebio Pharma, Senate Office of Public Records. Filings are due 20 days after each quarter ends.

From FEC filings: direct gifts this PAC reported, net of refunds · How we count

Gave directly to 14 sitting members of Congress in 2025–26.

Everyone this PAC fundsPro

See every candidate and member Bridgebio Pharma gave to directly, how much, and how its money splits between the parties.

This part is in Pro. A free account lets you follow up to 3 people and get a weekly email about them; upgrade whenever you need more.

Create a free account See what Pro adds Log in